The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • E-health company G Medical (GMV) has gained approval to join a U.S. over-the-counter market
  • The company is now tradable on the OTCQB under the code GMMVF
  • G Medical says it is looking to attract American individual and institutional investors
  • It plans to launch a shareholder engagement program in the U.S. soon
  • G Medical’s share price is up 12.12 per cent at midday trade
  • Shares in the company are now trading for 18 cents each

E-health company G Medical (GMV) has told shareholders it received U.S. approval to join over-the-counter market OTCQB. Company shares can now be traded under the code GMMVF.

On entering the American market, the company will have access to individual and institutional investors across the country.

G Medical detailed this will give it improved access to as its products gain popularity in the U.S. Additionally, it is expected to generate more growth opportunities.

“The company’s product suite is continuing to gain traction with medical organisations and healthcare professionals in the United States,” G Medical’s CEO Dr Yacov Geva said.

A medical smartphone case and a smart patch are two of the group’s popular products.

Dr Yacov outlined in today’s release the company is looking to begin securing American investors as it broadens its footprint in the country.

“An active shareholder engagement program is planned in the USA to ensure out investment attractions and growth prospects are highlighted amongst new investors,” he added.

After announcing the approval to the Australian market, G Medical’s share price is up 12.12 per cent at midday trade.

Shares in the company are now trading for 18 cents each.

gmv by the numbers
More From The Market Online
MEG scan concept AI gen

Compumedics snags sixth order for Orion LifeSpan at $4.2M heading to Shandong

Compumedics has inked a fresh $4.2M order to kick off CY26 with a sixth unit of…
A woman with a sign and a sad face

Last year’s anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in
AI concept

Codefai jumps +50% as DD over QuantumAI acquisition nears completion

Codefai Ltd (ASX:CDE), an Australian company that bills itself as an AI disruptor, has seen its shares soar 50%
Brain scan concept

Healthcare disruptor Compumedics clocks record sales in 1H FY26 at $33M; revenue up +32%

Compumedics has posted its highest-ever sales figure, netting $33M in the first half of FY26, also…